Clinical trial
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial…
NCT00477269 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00477269 |
|---|---|
| Title | Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension |
| Official title | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Arterial Hypertension |
| Intervention type | Drug |
| Interventions | Imatinib mesylate, Placebo |
| Enrollment | 59 |
| Start date | Apr 1, 2006 |
| Primary completion | Jan 1, 2014 |
| Completion | Jan 1, 2014 |
| First posted | May 23, 2007 |
| Last update posted | Mar 23, 2015 |
| Countries | Austria, Germany, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: